However, more human clinical validation is needed to determine whether the human autoimmune system alone is sufficient to complete human tumor clearance. 4.2. Solutions to ISAC development constraints Dual-target, dual-mechanism drugs need a balance between efficacy and safety. The ideal situation is ...